Reuters logo
BRIEF-AstraZeneca says Faslodex gets US FDA nod for expanded use in breast cancer
August 29, 2017 / 6:23 AM / 24 days ago

BRIEF-AstraZeneca says Faslodex gets US FDA nod for expanded use in breast cancer

Aug 29 (Reuters) - AstraZeneca Plc

* FASLODEX GETS US FDA OK FOR EXPANDED USE IN BREAST

* FASLODEX RECEIVES US FDA APPROVAL AS MONOTHERAPY FOR EXPANDED USE IN BREAST CANCER

* 20% REDUCTION IN DISEASE PROGRESSION VERSUS ANASTROZOLE, A CURRENT STANDARD TREATMENT OPTION

* 20% REDUCTION IN DISEASE PROGRESSION VERSUS ANASTROZOLE, A CURRENT STANDARD TREATMENT OPTION

* EXPANDED APPROVAL PROVIDES EARLIER BENEFIT FOR ADVANCED BREAST CANCER PATIENTS NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below